[{"id":"cbd3eb95-a6b5-4374-a565-cf5286d2e1ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05735366","created_at":"2023-02-21T16:01:47.196Z","updated_at":"2024-07-02T16:35:29.755Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05735366","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • SAIL66"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-11-09"}]